LON:SAG

LON:SAG - Science Group PLC

OPPORTUNISTIC BUYAWAIT ENTRYIndustrials - Consulting Services2026-08-08Data 35 days old580.00p

Conviction

out of 100

Executive Summary

Science Group PLC is a Cambridge-based, science-led technology and product development company that operates through two principal divisions: a technology and product development consultancy (formerly Sagentia) serving medical, consumer, food and beverage, and industrial clients, and Oakdene Hollins, a sustainability consultancy focused on food, drink, and agri-business. The group offers R&D services, technical consulting, regulatory support, and commercialisation assistance to a primarily UK and European client base, with a growing US presence in the medical and consumer verticals. It occupies a niche position as a small-cap specialist provider rather than a sector leader, with a market capitalisation of approximately GBP 235.92m.

The investment case rests on the durability of operating margins and consistent cash conversion at the consultancy level, with the near-term catalyst being the next scheduled annual results. Reported earnings of GBX 40.20 per share for the most recently reported quarter, combined with a dividend hike and ongoing share buybacks, support a mildly constructive view, but the earnings beat appears to have been flattered by a one-off disposal rather than purely recurring operations. The primary risk is client concentration, which is disclosed in regulatory filings and could disproportionately compress earnings if top relationships weaken, particularly against a conservative 2026 organic outlook.

OPPORTUNISTIC BUY. Conviction Score: 64/100. A confirmed step-change in organic revenue growth, visible contract wins, or M&A activity would lift the call; a deterioration in top-client relationships or a marked drop in cash conversion would force a downgrade.

Wait for entry. Current price 580.00p is 13.0% above the buy ceiling of 513.33p. New positions only below the ceiling.

AWAIT ENTRYOPPORTUNISTIC BUY · 64/100Now 580.00p · buy ≤ 513.33p · trim ≥ 600.00p

Thesis break: The investment thesis would be invalidated by the loss or material scaling-back of a disclosed top-10 client relationship, a sustained drop in cash conversion, or evidence that the recent earnings growth is non-recurring and cannot be replicated from underlying operations.

Business Model

Revenue is generated primarily through project-based engagements under a mix of fixed-fee and time-and-materials contracts. The technology and product development division typically takes clients from concept development and prototyping through regulatory compliance and commercialisation support, with the sustainability consultancy providing lifecycle analysis, carbon footprinting, and strategic advisory into food, drink, and agri-business clients. The model is people-intensive and requires low capital expenditure, which supports the mid-teens EBIT margins historically delivered by the group on roughly GBP 95m of FY2024 revenue.

Customers are predominantly UK and European corporates across medical devices, consumer products, food and beverage, and industrial end markets, with a growing share of US-based work in the medical and consumer verticals. Top-10 clients account for a meaningful share of group revenue, which generates both revenue stickiness through long-standing relationships and a meaningful concentration risk. The competitive moat is narrow but real: domain expertise across regulated industries, an established reputation in niche technical advisory, and the multi-disciplinary capability to take products from early-stage concept through to commercialisation create switching costs for clients with complex, multi-year development pipelines.

The earnings base reported in the most recent results has been supported partly by a one-off disposal rather than purely recurring operations, which is an important caveat when assessing the sustainability of the current earnings stream. Dividend distributions and ongoing share buybacks indicate management's view on capital allocation, but visible growth catalysts such as new contract wins, OEM deals, or M&A activity are not presently evidenced in the public record.

Financial Snapshot

Price

580.00p

Market Cap

235.6m

P/E Ratio

17.5x

52w High

612.00p

52w Low

520.00p

Distance from 52wH

-5.2%

Avg Volume

49934

Currency

GBX

Recent Catalysts

[17 March 2026] - Science Group issued earnings results for the most recently reported quarter, reporting earnings per share of GBX 40.20 according to Digital Look Earnings data. Source: Markets Daily.

[13 April 2026] - The shares hit a new 52-week high following the recent earnings release, with the 52-week high subsequently reaching 612p. Source: Markets Daily.

[1 May 2026] - Science Group announced a transaction in own shares, with treasury share movements disclosed via a regulatory announcement (RNS). Source: Stockopedia (regulatory news feed).

[May 2026] - Science Group executed a share buyback, repurchasing 20,000 ordinary shares of 1 pence each to tighten the share base. Source: TipRanks (company announcement).

[2026 (date unconfirmed)] - A further targeted share buyback was disclosed in a separate company announcement to tighten the capital base. Source: TipRanks (company announcement).

Thesis Evaluation

Bull Case (32% weight)

The bull case requires the consultancy to deliver sustained mid-teens EBIT margins, for cash conversion to remain consistent, and for the recently reported earnings momentum to be confirmed as predominantly organic rather than driven by the one-off disposal. Visible contract wins or M&A activity would meaningfully reinforce this scenario. Price target of 720p over a 12-month horizon reflects re-rating towards peer multiples and a modest premium for execution.

Base Case (49% weight)

Margins hold in the mid-teens, cash conversion stays reliable, and the share buyback programme continues to provide a technical floor, but no major contract wins or corporate actions emerge. The market continues to apply a discount to reflect client concentration risk. Price target of 600p over a 12-month horizon represents modest upside on continued capital returns and earnings stability.

Bear Case (19% weight)

A top-client relationship weakens or is lost, the one-off contribution to earnings is not repeated, and cash conversion deteriorates against a conservative 2026 organic outlook, exposing the limited depth of the visible catalyst pipeline. Price target of 470p over a 12-month horizon reflects a de-rating back towards the lower half of the 52-week range as the market re-prices concentration risk.

Weighted conviction:Bull (32%) x 100 + Base (49%) x 62 + Bear (19%) x 10 = 64/100. OPPORTUNISTIC BUY.

Key Risks

Client Concentration Risk: Top-10 clients account for a meaningful share of group revenue, so the loss or material scaling-back of a single relationship could disproportionately pressure earnings. Estimated probability: 30%. Impact: severe.
Earnings Quality Risk: Recent strong profit growth appears partly supported by a one-off disposal rather than purely recurring operations, which raises questions about the sustainability of the current earnings trajectory. Estimated probability: 50%. Impact: moderate.
Limited Visible Growth Catalysts: The public record evidences no major contract wins, OEM deals, or M&A activity, leaving the thesis reliant on margin durability and capital returns rather than visible growth. Estimated probability: 60%. Impact: moderate.
Liquidity and Small-Cap Discount Risk: With a market capitalisation of approximately GBP 235.92m, the shares may continue to trade at a discount to larger R&D services peers due to limited liquidity and float. Estimated probability: 55%. Impact: low.
Organic Growth Outlook Risk: Management's conservative 2026 organic outlook limits the room for positive earnings surprises if end-market demand softens across medical, consumer, food and beverage, or industrial clients. Estimated probability: 40%. Impact: moderate.

Who Should Own It / Avoid It

Ideal for: Long-term, patient investors with a moderate risk tolerance who are comfortable with small-cap UK equities and are seeking exposure to niche, science-led consulting services. The position is best held with a minimum holding period of 12 to 24 months to allow the dividend, buyback programme, and any incremental contract activity to translate into a re-rating. Investors should be able to tolerate meaningful single-stock volatility and accept that visible catalysts are limited.

Avoid if: Investors requiring frequent, identifiable catalysts or those unwilling to underwrite a client-concentration risk that is disclosed in regulatory filings. Traders seeking short-term momentum drivers, investors with a low tolerance for small-cap liquidity risk, and anyone unable to absorb a drawdown towards the 52-week low of 520p should not hold this position. Those who need visibility on recurring earnings quality before adding exposure should also wait for further organic growth confirmation.

Recommendation

BLOCKED - methodology gate failed (frameworkRuleCheck). The model score is 64/100 (OPPORTUNISTIC BUY), but this is not an actionable recommendation until the gate is verified.

Entry levels under review.

Conviction Trend

Latest conviction: 64/100. Trend versus prior report: Flat.

CONVICTION BUY (80+)BUY (65 - 79)OPP BUY (50 - 64)SPEC BUY (30 - 49)AVOID (0 - 29)

Report date	Conviction
2026-08-08	64
2026-07-25	64
2026-06-28	59
2026-05-30	64
2026-04-27	64

See the trade-card view →

Sources

Market data: DYOR HQ proprietary market data workflow.

Public sentiment and news flow: Public news flow, company earnings releases, regulatory announcements (RNS), investor day materials, web research, and analyst commentary drawn from financial news wires and aggregators.

Primary source types: Regulatory filings (RNS announcements), company press releases, earnings results disclosures, company investor relations materials, regulatory news feeds, and third-party financial news wires.

Key sources

Data correct as of 2026-08-08